Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma